CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Medicinova Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Medicinova Inc
SUITE 650, 4275 EXECUTIVE SQUARE
Phone: (858) 373-1500p:858 373-1500 LA JOLLA, CA  92037  United States Ticker: 48754875

Business Summary
MediciNova, Inc. is a biopharmaceutical company. The Company is focused on developing therapeutics for the treatment of serious diseases with unmet medical needs and a commercial focus on the United States market. It is focused on its development activities on MN-166 (ibudilast) and MN-001 (tipelukast). Its ibudilast is for neurological and other disorders, such as progressive multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, substance dependence and addiction, and prevention of acute respiratory distress syndrome. Its tipelukast is for fibrotic diseases, such as nonalcoholic fatty liver disease (NAFLD) and idiopathic pulmonary fibrosis (IPF). The Company's pipeline also includes MN-221 (bedoradrine) for the treatment of acute exacerbation of asthma and MN-029 (denibulin) for solid tumor cancers. Its ibudilast is in development for various neurological diseases and other diseases.
(Source: 10-K)

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
Moody's
Rating
Fitch
Rating
DBRS
Rating
YesYes-----

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
6/30/202312/31/2022Yes----

Officers and Directors

Title

Name

Age
Title
Date
Start
Date
President, Chief Executive Officer, Director YuichiIwaki 73 6/19/2020 9/1/2000
Chief Financial Officer Jason J.Kruger 46 6/16/2022 6/16/2022
Vice President Geoffrey G.O'brien 54 10/16/2013 1/1/2009
5 additional Officers and Directors records available in full report.

Business Names
Business Name
4875
Avigen, Inc.
MediciNova (Europe) Ltd.
MediciNova Japan, Inc.
MediciNova, Inc.

General Information
Number of Employees: 13 (As of 12/31/2022)
Outstanding Shares: 49,046,246 (As of 6/30/2023)
Shareholders: 11
Stock Exchange: TYO
Fax Number: (858) 404-0048


Copyright © 2023 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Wednesday, September 27, 2023